Five Arrows Principal Investments, the European private equity arm of Rothschild, agreed to acquire Sygnature Discovery, an integrated drug discovery and non-clinical solutions provider, from Phoenix Equity Partners, a private equity firm. Financial terms were not disclosed. “Our partnership with the Phoenix team has been invaluable; they shared our ambitions for the Company and were instrumental in helping us with our acquisition strategy. We are delighted to welcome Five Arrows as a shareholder alongside the Sygnature team and are excited about what the future holds for our Company," Simon Hirst, Sygnature CEO.